Emmanuelle Ferrant
Overview
Explore the profile of Emmanuelle Ferrant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharman J, Egyed M, Jurczak W, Skarbnik A, Pagel J, Flinn I, et al.
Leukemia
. 2024 Dec;
39(2):529.
PMID: 39627506
No abstract available.
2.
Sesques P, Karlin L, Massy E, Maarek A, Aussedat G, Lazareth A, et al.
Front Oncol
. 2024 Nov;
14:1436587.
PMID: 39544298
Background: In spite of spectacular advances in the treatment of multiple myeloma, a majority of patients will die from this disease or related complications. While a great amount of focus...
3.
Guieze R, Ysebaert L, Roos-Weil D, Fornecker L, Ferrant E, Molina L, et al.
Nat Commun
. 2024 Aug;
15(1):6822.
PMID: 39122717
Richter transformation (RT) is an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia. Here we investigated the anti-CD3/anti-CD19 T-cell-engager blinatumomab after R-CHOP (i.e. rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...
4.
Le Lan C, Belot A, Golfier C, Audin B, Sesques P, Bernier A, et al.
Hematol Oncol
. 2024 Jul;
42(4):e3297.
PMID: 38989917
No abstract available.
5.
Robak T, Doubek M, Ferrant E, Diels J, Andersone L, Wilbertz S, et al.
Curr Med Res Opin
. 2024 Jun;
40(8):1369-1378.
PMID: 38885086
Objective: To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed...
6.
Michallet A, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy M, et al.
Blood Adv
. 2023 Apr;
7(15):3936-3945.
PMID: 37026799
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07...
7.
Bourbon E, Chabane K, Mosnier I, Bouvard A, Thonier F, Ferrant E, et al.
J Mol Diagn
. 2023 Feb;
25(5):274-283.
PMID: 36773701
Current guidelines for patients with chronic lymphocytic leukemia (CLL) recommend mutation status determination of the clonotypic IGHV gene before treatment initiation to guide the choice of first-line therapy. Currently, commercially...
8.
Sortais C, Cordeil S, Bourbon E, Idlhaj M, Ferrant E, Safar V, et al.
Leuk Lymphoma
. 2022 Dec;
64(3):707-711.
PMID: 36573418
No abstract available.
9.
Algrin C, Perol L, Chapiro E, Baseggio L, Maloum K, Settegrana C, et al.
Haematologica
. 2022 Dec;
108(6):1691-1696.
PMID: 36546425
No abstract available.
10.
HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
Bourbon E, Sesques P, Gossez M, Tordo J, Ferrant E, Safar V, et al.
Blood Adv
. 2022 Apr;
7(5):744-755.
PMID: 35439292
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged...